Back to top
more

ProPhase Labs (PRPH)

(Delayed Data from NSDQ)

$2.46 USD

2.46
5,972

+0.06 (2.50%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $2.48 +0.02 (0.81%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ProPhase Labs, Inc. (PRPH) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 233.33% and 28.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) closed at $10.47 in the latest trading session, marking a -1.87% move from the prior day.

Strength Seen in ProPhase Labs, Inc. (PRPH): Can Its 8% Jump Turn into More Strength?

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks.com featured highlights include USA Truck, Franklin Covey, ProPhase Labs, Daqo New Energy and The Chefs' Warehouse

by Zacks Equity Research

USA Truck, Franklin Covey, ProPhase Labs, Daqo New Energy and The Chefs' Warehouse are part of zacks screen of the week article.

Nalak Das headshot

5 Stocks With Recent Price Strength for a Steady Portfolio

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are USAK, FC, PRPH, DQ and CHEF.

ProPhase Labs, Inc. (PRPH) Soars 9.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.

ProPhase Labs, Inc. (PRPH) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ProPhase Labs, Inc. (PRPH) Surges 7.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Is ProPhase Labs (PRPH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ProPhase Labs, Inc. (PRPH) and RVL Pharmaceuticals PLC (RVLP) have performed compared to their sector so far this year.

Reata (RETA) Up More Than 12% YTD: What's Driving the Rally?

by Zacks Equity Research

Reata's (RETA) prospects are likely to improve following the potential approval of its lead candidate, omaveloxolone, expected by the end of 2022 is likely driving its share price.

Axcella (AXLA) Up on Decision to Prioritize Long-COVID Program

by Zacks Equity Research

Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 studies.

    Reata (RETA) Friedreich's Ataxia NDA Gets Priority Review

    by Zacks Equity Research

    Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. The FDA grants priority review to the NDA for the same. Stock rises.

    Esperion (ESPR) Up More Than 12% YTD: What's Driving the Rally?

    by Zacks Equity Research

    Esperion's (ESPR) marketed drugs are the key drivers of the stock. Sales of the drugs increase more than 100% during the first quarter. Strong sales growth is expected to continue in 2022 as well as 2023.

    Has ProPhase Labs (PRPH) Outpaced Other Medical Stocks This Year?

    by Zacks Equity Research

    Here is how ProPhase Labs, Inc. (PRPH) and RVL Pharmaceuticals PLC (RVLP) have performed compared to their sector so far this year.

    United Therapeutics (UTHR) Gains on Tyvaso DPI Approval

    by Zacks Equity Research

    The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.

    ProPhase Labs, Inc. (PRPH) Moves to Strong Buy: Rationale Behind the Upgrade

    by Zacks Equity Research

    ProPhase Labs, Inc. (PRPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

    Best Momentum Stocks to Buy for May 24th

    by Zacks Equity Research

    PRPH, GOGL, and ERF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 24, 2022.

    ProPhase Labs, Inc. (PRPH) Tops Q1 Earnings and Revenue Estimates

    by Zacks Equity Research

    ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 74.36% and 95.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    FibroGen (FGEN) delivered earnings and revenue surprises of 19.05% and 120.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up

    by Zacks Equity Research

    United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

    Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -86.54% and 49.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Cloudflare (NET) to Report Q1 Earnings: What's in Store?

    by Zacks Equity Research

    Cloudflare's (NET) Q1 results are likely to reflect increased demand for security solutions that became imperative by aggravated cyberattacks amid the pandemic-led work and learn from home policies.